X4 PHARMACEUTICALS, INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
X4 PHARMACEUTICALS, INC (XFOR) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$17.00 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- X4 PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$17.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month |
|---|---|
| 2017-03-31 | -$17.00K 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |